LoA Update: Merus’ zenocutuzumab has a five-point increase in chances for transition to next …,

The estimated primary completion date for the study is in September 2021, according to ClinicalTrials.gov. Zenocutuzumab acts by binding to Her2 …, The estimated primary completion date for the study is in September 2021, according to ClinicalTrials.gov. Zenocutuzumab acts by binding to Her2 …, Read More

Scroll to Top